Reduced expression of the cell cycle inhibitor p27(Kip1) in non-small cell lung carcinoma: A prognostic factor independent of ras

Cancer Research

Volumn 59, Issue 3, 1999, Pages 684-688

  Catzavelos, Charles ^b   Tsao, Ming Sound ^a,b   DeBoer, Gerrit ^b,c   Bhattacharya, Nandita ^b   Shepherd, Frances A ^a   Slingerland, Joyce M ^b,c  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P27;

ARTICLE; CANCER GRADING; DIAGNOSTIC VALUE; GENE MUTATION; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; ONCOGENE RAS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION;

CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P27; GENES, RAS; HUMANS; LUNG NEOPLASMS; MICROTUBULE-ASSOCIATED PROTEINS; MUTATION; NEOPLASM STAGING; PROGNOSIS; TUMOR SUPPRESSOR PROTEINS;

EID: 0033083047     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Hunter, T., and Pines, J. Cyclins, and cancer II. Cyclin D and cdk inhibitors come of age. Cell. 79: 573-582, 1994.
2. Morgan, D. O. Principles of cdk regulation. Nature (Lond.), 374: 131-134, 1995.
3. Sherr, C. J. G1 phase progression: cycling on cue. Cell, 79: 551-555, 1994.
4. Sherr, C. J., and Roberts, J. M. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev., 9: 1149-1163, 1995.
5. Reed, S. I., Bailly, E., Dulic, V., Hengst, L. Resnitzky, D., and Slingerland, J. G1 control in mammalian cells. J. Cell Science, 18 (Suppl.): 69-73, 1994.
6. Norbury, C., and Nurse, P. Animal cell cycles and their control. Annu. Rev. Biochem., 61: 441-470, 1992.
7. Solomon, M. J. Activation of the various cyclin/cdc2 proteins. Curr. Opin. Cell Biol., 5: 180-186, 1993.
8. Pagano, M., Tam, S. W., Theodoras, A. M., Beer-Romero, P., Del Sal, G., Chau, V., Yew, P. R., Draetta, G. F., and Rolfe, M. Role of ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science (Washington DC), 269: 682-685, 1995.
9. Kip1. EMBO J., 16: 5334-5344, 1997.
10. Sheaff, R. J., Groudine, M., Gordon, M., Roberts, J. M., and Clurman, B. E. Cyclin E-CDK2 is a regulator of p27Kip1. Genes Dev., 11: 1464-1478, 1997.
11. Kip1: chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors. Cancer Res., 55: 1211-1214, 1995.
12. Kip1 gene to 12p13 and its analysis in leukemias. Cancer Res., 55: 1206-1210, 1995.
13. Ferrando, A., Balbin, M., Pendas, A. M., Vizoso, F., Velasco, G., and Lopez-Otin, C. Mutational analysis of the human cyclin-dependent kinase inhibitor p27Kip1 in primary breast carcinomas. Hum. Genet., 97: 91-94, 1996.
14. Kip1 in human malignancies. Cancer Res., 55: 2266-2269, 1995.
15. Catzavelos, C., Bhattacharya, N., Ung, Y. C., Wilson, J. A., Roncari, L., Sandhu, C., Shaw, P., Yeger, H., Morava-Protzner, I., Kapusta, L., Franssen, E., Pritchard, K. I., and Slingerland, J. M. Decreased levels of the cell cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat. Med., 3: 227-230, 1997.
16. Porter, P. L., Malone, K. E., Heagerty, P. J., Alexander, G. M., Gatti, L. A., Firpo, E. J., Daling, J. R., and Roberts, J. M. Expression of cell cycle regulators p27kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat. Med., 3: 222-225, 1997.
17. Tan, P., Cady, B., Wanner, M., Worland, P., Cukor, B., Magi-Galluzzi, C., Lavin, P., Draetta, G., Pagano, M., and Loda, M. The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a, b) invasive breast carcinomas. Cancer Res., 57: 1259-1263, 1997.
18. Loda, M., Cukor, B., Tam, S. W., Lavin, P., Florentino, M., Draetta, G. F., Jessup, J. M., and Pagano, M. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat. Med., 3: 231-234, 1997.
19. Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res., 58: 542-548, 1998.
20. Mori, M., Mimori, K., Shiraishi, T., Tanaka, S., Ueo, H., Sugimachi, K., and Akiyoshi, T. p27 expression and gastric carcinoma. Nat. Med., 3: 593, 1997.
21. Mountain, C. F. New prognostic factors in lung cancer. Biologic prophets of cancer cell aggression. Chest, 108: 246-254, 1995.
22. Moore, J. D. F., and Lee, J. S. Staging and prognostic factors: non-small cell lung cancer. In: H. I. Pass, J. B. Mitchell, D. H. Johnson, and A. T. Turrisi (eds.), Lung Cancer: Principles and Practice, pp. 481-494. Philadelphia: Lippincott-Raven Publishers, 1996.
23. Rodenhuis, S., and Slebos, R. J. C. Clinical significance of ras oncogene activation in human lung cancer. Cancer Res., 52: 2665s-2669s, 1992.
24. Sugio, K., Ishida, T., Yokoyama, H., Inoue, T., Sugimachi, K., and Saszuki, T. ras gene mutation as a prognostic marker in adenocarcinoma of the human lung without lymph node metastasis. Cancer Res., 52: 2903-2906, 1992.
25. Mitsudomi, T., Sterinberg, S. M., Oie, H. K., Mulshine, J. L., Phelps, R., Vialleet, J., Pass, H., Minna, J. D., and Gazdar, A. F. ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent. Cancer Res., 51: 4999-5002, 1991.
26. WHO. Histological typing of lung tumors. Am. J. Clin. Pathol., 77: 123-136, 1982.
27. Mountain, C. F. A new international staging system for lung cancer. Chest, 89: 225s-233s, 1986.
28. Liu, C., and Tsao, M. S. Proto-oncogene and growth factor/receptor expression in the establishment of primary human non-small cell lunch carcinoma cell lines. Am. J. Pathol., 142: 413-423, 1993.
29. Tsao, M., Liu, N., Nicklee, T., Shepherd, F., and Viallet, J. Angiogenesis correlates with vascular endothelial growth factor expression but not with Ki-ras oncogene activation in non-small cell lung carcinoma. Oncogene, 3: 1807-1814, 1997.
30. Kaplan, E. L., and Meier, P. Nonparametric estimation from incomplete observations. Am. Stat. Assoc. J., 53: 457-481, 1958.
31. Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., and Smith, P. G. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br. J. Cancer. 35: 1-39, 1977.
32. Esposito, V., Baldi, A., De Luca, A., Groger, A. M., Loda, M., Giordano, G. G., Caputi, M., Baldi, F., Pagano, M., and Giordano, A. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res., 57: 3381-3385, 1997.
33. St. Croix, B., Florenes, V., Rak, A., Flanagan, J. W., Bhattacharya, N., Slingerland, J. M., and Kerbel, R. S. Impact of the cyclin dependent kinase inhibitor p27Kip1 on adhesion-dependent resistance of tumor cells to anticancer agents. Nat. Med., 2: 1204-1210, 1996.
34. Radeva, G., Petrocelli, T., Behrend, E., Leung-Hagesteijn, C., Filmus, J., Slingerland, J., and Dedhar, S. Overexpression of the integrin linked kinase promotes anchorage-independent cell cycle progression. J. Biol. Chem., 272: 13937-13944, 1997.
35. Zhu, X., Ohtsubo, M., Bohmer, R. M., Roberts, J. M., and Assoian, R. K. Adhesion-dependent cell cycle progression linked to the expression of cyclin D1, activation of cyclin E-cdk2, and phosphorylation of the retinoblasloma protein. J. Cell Biol., 133: 391-403, 1996.
36. Fang, F. G., Watanabe, N., Hunter, T., and Ruoslahti, E. Dependence of cyclin E-cdk2 kinase activity on cell anchorage. Science (Washington DC), 271: 499-502, 1996.
37. Assoian, R. K. Anchorage-dependent cell cycle progression. J. Cell Biol., 136: 1-3, 1997.
38. Fero, M. L., Rivkin, M., Tasch, M., Porter, P., Carow, C. E., Polyak, K., Firpo, E., Tsai, L., Broudy, V., Perlmutter, R. M., Kaushansky, K., and Roberts, J. M. A syndrome of multi-organ hyperplasia with features of gigantism, tumorigenesis and female sterility in p27Kip1-deficient mice. Cell, 85: 733-744, 1996.
39. Kiyokawa, H., Kineman, R. D., Manova-Todorova, K. O., Soares, V. C. Hoffman, E. S., Ono, M., Khanam, D., Hayday, A. C., Frohman, L. A., and Koff, A. Enhanced growth of mice lacking the cyclin-dependem kinase inhibitor function of p27Kip1. Cell. 85: 721-732, 1996.
40. Nakayama, K., Ishida., N., Shirane, M., Inomata, A., Inoue, T., Shishido, N., Horii, I., Loh, D. Y., and Nakayama, K. Mice lacking p27Kip1 display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell, 85: 707-720, 1996.
41. Kip1. J. Cell Biol., 142: 557-571, 1998.
42. Kip1 in human lung cancers: differential changes in small cell and non-small cell carcinomas. Cancer Res., 58: 1042-1047, 1998.
43. Slingerland, J. M., and Tannock, I. Control of cell proliferation and cell death. In: I. Tannock and R. P. Hill (eds.), Basic Science of Oncology. McGraw-Hill. 1997.
44. Kawada, M., Yamagoe, S., Murakami, Y., Suzuki, K., Mizuno, S., and Uehara, Y. Induction of p27Kip1 degradation and anchorage independence by Ras through the MAP kinase signaling pathway. Oncogene, 15: 629-637, 1997.
45. 1 phase required for p27kip1 down-regulation, passage through the restriction point, and entry into S phase in growth factor-stimulated NIH 3T3 fibroblasts. Mol. Cell. Biol., 17: 5348-5358, 1997.
46. Kip1. Mol. Cell. Biol., 17: 3850-3857, 1997.
47. Westra, W. H., Baas, I. O., Hruban, R. H., Askin, F. B., Wilson, K., Offerhaus, G. J., and Slebos, R. J. K-ras oncogene activation in atypical alveolar hyperplasias of the human lung. Cancer Res., 56: 2224-2228, 1996.
48. Keohavong, P., DeMichele, M. A. A., Melacrinos, A. C., Landrencau, R. J., Weyant, R. J., and Siegfried, J. M. Detection of K-ras mutations in lung carcinomas: relationship to prognosis. Clin. Cancer Res., 2: 411-418, 1996.